Leading Academic Medical Centers to Present New AI-ECG Research on Viz.ai’s Cardio Suite at AHA 2026

MyoKardia, a Bristol Myers Squibb company, provided study support through a funding agreement with Viz.ai.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Studies from Beth Israel Deaconess and the University of Colorado highlight how AI-ECG can help clinicians identify suspected cardiac disease from routine ECGs

SAN FRANCISCO--(BUSINESS WIRE)-- Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that two research abstracts evaluating its AI-powered electrocardiogram (AI-ECG) technology within the Viz Cardio Suite have been accepted for presentation at the Hypertrophic Cardiomyopathy Medical Society (HCMS) meeting, held in conjunction with the American Heart Association’s Scientific Sessions 2026 in Chicago. Both studies focus on Viz HCM, the suite’s AI-ECG algorithm for detecting hypertrophic cardiomyopathy (HCM), a frequently underdiagnosed form of cardiac disease.

Despite significant advances in treatment for hypertrophic cardiomyopathy (HCM), an estimated 85% of patients may remain undiagnosed, underdiagnosed, or misdiagnosed,¹ highlighting the need for better tools to identify patients who could benefit from earlier intervention and specialty care. The Viz HCM solution was developed as part of a multi-year agreement between Viz.ai and Bristol Myers Squibb (NYSE: BMY) aimed at transforming how HCM is identified and managed. Viz HCM was the first FDA-cleared AI algorithm designed to help clinicians detect signs of HCM using a standard 12-lead ECG.²

The new studies, conducted by investigators at Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital, and the University of Colorado, highlight AI-ECG technology's potential to identify patients who may be missed by traditional detection methods.

“We've been using ECGs for decades, but we're still discovering just how much they can tell us,” said Jordan B. Strom, MD, MSc, of Beth Israel Deaconess Medical Center. “In our study, Viz HCM added meaningful information beyond standard ECG interpretation in identifying patients with suspected disease. This opens up exciting possibilities for how we use a test we already rely on every day to better evaluate and care for patients.”

With 21 clinical abstracts and studies presented to date, Viz HCM has been evaluated across academic and real-world clinical settings, contributing to a growing body of evidence supporting its clinical utility.

“Most patients with HCM are never diagnosed, and the ones who are often wait years. What these two studies show is that the ECGs that health systems are already collecting contain the signal to change that,” said Tim Showalter, MD, Chief Medical Officer at Viz.ai. “Collaborations like these are essential to advancing our understanding of what’s possible with the technology within the Viz Cardio Suite and bringing these innovations into everyday clinical care, where they can make a meaningful difference for patients.”

Key findings from the studies being presented at the event include:

• “Artificial Intelligence Electrocardiogram Analysis Compared with Diagnosis Code-Based Ascertainment for Hypertrophic Cardiomyopathy in a Real-World Electronic Health Record Cohort” — Conducted by researchers at the University of Colorado, the study analyzed ECGs from more than 29,000 patients and found that nearly 40% of those flagged by Viz HCM for suspected HCM had no corresponding diagnosis code in their medical records. The findings suggest AI-ECG may complement traditional diagnosis-code-based approaches to identifying patients who might otherwise never reach a specialist for further evaluation.
• “Artificial Intelligence-Enabled Algorithm for Detection of Hypertrophic Cardiomyopathy Compared with a Standard Electrocardiogram” — In a Beth Israel Deaconess Medical Center study, the Viz AI-ECG algorithm identified suspected HCM beyond what standard ECG measurements could, and patients flagged by the algorithm had a 2.68-fold higher hazard of adverse clinical events.

To learn more about Viz.ai and the technology available within the Viz Cardio Suite, visit https://www.viz.ai/cardio.

About Viz.ai
Viz.ai is the leader in building and deploying AI-powered Care Pathways and helping doctors do their work. The Viz Platform is deployed in 2,000 hospitals across the United States and trusted by many of the leading life sciences companies. The platform uniquely combines real-time, multimodal clinical data with deep clinician engagement to detect disease earlier, coordinate care teams, and help ensure patients receive the right treatment faster. Viz.ai was the first company awarded CMS reimbursement for AI and is ranked the #1 Healthcare AI Platform by hospitals and health systems in the Black Book Research survey. For more information, visit Viz.ai.

Funding
Support for the current study provided by MyoKardia, Inc., a Bristol Myers Squibb company, through a funding agreement with Viz.ai.

References

1. Maron MS et al., “Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States,” Am J Cardiol 2016;117(10):1651–1654
2. FDA De Novo DEN230003, August 2023.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261106195617/en/

Media Contact
Caroline Rueve
viz.ai@solcomms.co

Source: Viz.ai

Key Terms

electrocardiogram medical

An electrocardiogram (ECG or EKG) is a simple, noninvasive test that records the heart’s electrical signals through sensors on the skin and displays them as a waveform showing heart rate and rhythm. For investors, ECGs are important because they are a primary tool for diagnosing heart conditions, monitoring safety and effectiveness in clinical trials, and driving demand for medical devices and services—like a dashboard gauge revealing whether a car’s engine is healthy.

hypertrophic cardiomyopathy medical

Hypertrophic cardiomyopathy is a genetic heart condition in which the heart muscle becomes abnormally thick, making it harder for the heart to pump and for electrical signals to travel normally; think of a pump whose walls have thickened so it moves less efficiently. Investors care because the condition drives demand for diagnostics, drugs and devices, affects workforce and insurance costs, and can influence clinical trial results, regulatory approvals and liability exposure in healthcare-related companies.

12-lead ECG medical

A 12-lead ECG (electrocardiogram) is a common medical test that records the heart’s electrical activity from 12 different viewpoints using sensors on the chest and limbs—like taking a multi-angle snapshot of the heart’s rhythm and signals. It matters to investors because it is a routine tool for detecting heart problems and monitoring safety in clinical trials and product use; abnormal findings can influence regulatory decisions, trial outcomes, or a healthcare company's market value.

FDA-cleared regulatory

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.